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There is discussion over the benefit of continuing cervical screening in women over the age of 50 with a history of negative cytology.
We aimed to determine the risk of abnormal cytology in such women. Screening history data from 1985 to 2003 were obtained for a
cohort of 2 million women from the NHS cervical screening programme from four Health Authorities in England. The 57651 women
in the cohort who reached age 40 between 1 January 1985 and 31 December 1990 and had at least one routine or opportunistic
smear between ages 50 and 54 were included in the analysis. Exposure groups (negative cytology history, negative but including
inadequate smears, and positive history) were defined on the basis of screening histories from ages 40 to 49. Sixty-four percent
(134/206) (95% CI: 57–71%) of the moderate dyskaryosis or worse lesions at ages over 50 were detected from women in the
negative smear history group. After allowance for time since last negative smear, the relative risk for the first primary smear over the
age of 50 having moderate dyskaryosis or worse decreased from 0.60 (95% CI: 0.41–0.84) for two negative smear episodes to 0.25
(95% CI: 0.10–0.56) for four negative smear episodes, compared with the positive history group. If screening were discontinued for
all women over 50 with a negative history, the majority of cytological abnormalities now being detected at these ages that lead
directly to referral to colposcopy would be missed.
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There has been much discussion since the early 1990’s about the
benefit of continuing cervical screening in women over the age 50
years with a history of repeated negative cytology. It has been
suggested that such women are at very low risk of having
pre-invasive lesions and therefore of developing invasive cancer,
and that ceasing screening in this group could alleviate anxiety
and enable better allocation of resources (Van Wijngaarden and
Duncan, 1993; Cruickshank et al, 1997).
Cervical screening aims to prevent the occurrence of invasive
cancer by detecting pre-invasive lesions (CIN 1, 2 and 3). The
prevalence of pre-invasive cervical lesions decreases with age and
women screened over the age of 50 have a considerably lower risk
of having abnormal cytology results. The risk of mild or worse
dyskaryosis varies from around 10% for women in their early
twenties to only around 1% for women over 50 years (Cervical
screening programme, England 2007–08 statistical bulletin).
The rate of progression of most lesions destined to become
invasive cancer is generally considered to be slow, and one might
therefore anticipate that a negative smear history before the age
of 50 would considerably reduce the risk of positive cytology
or histology in women aged 50–64 years (the upper age of
invitation to screening in the UK), who have been regularly
screened. In the 1990’s it was suggested, based on evidence from
the Tayside area of Scotland, that women over the age of 50 years
with an adequate history of negative results on smear testing
every 3 years may be safely discharged from further screening
(Van Wijngaarden and Duncan, 1993). There have been few
studies to test this, however (Cruickshank et al, 1997; Flannelly
et al, 2004; Armaroli et al, 2008), and the only large study directly
considering the question had relatively short screening histories
(Flannelly et al, 2004).
We have therefore undertaken a large cohort study to investigate
the risk of a positive primary smear result at the first routine recall
episode after the age of 50 years in women with a negative smear
history at ages 40–49 years compared with women with other
histories, and how the number of negative smears relates to this
risk.
METHODS
We assembled a population-based cohort of 2 million women from
four health authorities (two areas invited 3 yearly and two other
areas 5 yearly) in England with cervical screening histories
covering the period 1 January 1985 to around March 2004 (the
exact date dependent on the area of residence), using information
obtained from the national computerised call-recall system.
Women within this cohort with dates of birth between 1 January
1945 and 31 December 1950 and still resident and eligible in the
same areas for invitation to screening at March 2004 have been
included in the current analysis. These women reached age of 40
years between 1 January 1985 and 31 December 1990 (around the
start of the national computerised call-recall system circa 1988)
and we have details on the computerised system of 10 years of
screening history between ages of 40 and 49 years and a minimum
of 3 years follow-up after reaching age of 50 years.
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yFor analysis, we divided the screening histories into ‘episodes’
starting with a routine or opportunistic (‘primary’) smear and
ending with a (‘closing’) smear that returned the woman back to
routine recall or cessation of screening (e.g., because of a hysterec-
tomy). For most episodes the primary smear was negative with an
action of return to routine recall, and therefore the primary smear
was also the closing smear. We included in our analysis women in
the cohort with a primary smear between the ages of 50 and 54
years; these are therefore routine or opportunistic smears and not
repeat or follow-up tests. The cohort and our use of episodes is
described in detail in an earlier paper (Blanks et al, 2007).
We allocated women to three groups for analysis on the basis of
their screening history between ages of 40 and 49 years. ‘Negative’
history was defined as at least two episodes, all of which were single
smear episodes with a negative result and an action of return to
routine recall. ‘Inadequate’ history was defined as one or more
episodes that included an inadequate smear result, but no abnormal
cytology results. ‘Positive’ history was defined as one or more
episodes that included a smear with results of borderline abnormal
cytology or worse. Women with smear histories consisting of only
one negative episode were not included in the study.
The main outcome measure was the prevalence of cytological
disease in the primary smear from the first episode starting after
the age of 50 years, with the additional criterion that the episode
must have occurred before age of 55 years. We analysed the
prevalence ratio (also alluded to in the text as relative risk) of
cytological disease in this first primary smear over 50 years in the
‘negative’ compared with the ‘positive’ group and the effect of
increasing numbers of negative episodes before age of 50 years. A
logistic regression analysis was used to determine any confounding
effect of duration between the last smear under age 50 years and
the first smear after age of 50 years, because the length of this
interval affects the risk of abnormality after age of 50 years, and
could be related to whether the earlier smear was positive,
inadequate or negative and the frequency of past screening. The
exposure of two, three or four negative smear episodes before age
of 50 years was entered into the model as a categorical variable.
There were four final models with outcomes of, respectively,
borderline disease or worse; mild dyskaryosis or worse; moderate
dyskaryosis or worse and severe dyskaryosis or worse. The
outcomes of the models were odds ratios, but these can be treated
as relative risks as the vast majority of women (with adequate
smear results) will have negative results and therefore positive
cytological disease outcomes can be considered rare.
In addition, the probability of referral to colposcopy during the
first episode after age of 50 years was calculated for ‘negative’,
‘positive’ and ‘inadequate’ groups and the prevalence ratio of
referral to colposcopy for the ‘negative’ and ‘inadequate’ groups
relative to the ‘positive’ group was calculated. All statistical
analyses were conducted using STATA version 8 (StataCorp,
College Station, TX, USA).
To examine the effects of 3- and 5-yearly screening policy, we
examined the probability of women with negative smear histories
of either two or three episodes between the ages of 40 and 49 years
having a primary smear result of mild dyskaryosis or worse at their
first episode after age of 50 years.
RESULTS
There were 71283 women in the three exposure groups defined by
their screening history between ages of 40 and 49 years, of whom
57671 (81%) also had a primary smear between the ages of 50 and
54 years and were therefore included in the analysis. Of these,
42124 were in the ‘negative’ group, 7056 in the ‘inadequate’ group
and 8471 in the ‘positive’ group. The group of women included in
the study reached age of 50 years between 1 January 1995 and 31
December 2000 and the study outcome primary smears occurred
between 9 January 1995 and 17 March 2004. The mean age for the
outcome primary smear was 51.4 years (s.d. 1.2 years).
Table 1 shows details of the primary smear results for the first
screening episode over the age of 50 years for the three study
groups. The ‘negative’ group had a higher proportion of negative
smear results (91.7%) from the first smear over 50 years compared
with the ‘inadequate’ (88.1%) and ‘positive’ (89.4%) groups. The
‘inadequate’ group, however, had a notably higher proportion of
inadequate smear results, suggesting that an earlier inadequate
smear history is predictive of future inadequate smears. Table 1
also shows the proportion of adequate smears with moderate
dyskaryosis or worse for all three groups, with 95% confidence
limits. Of 209 moderate dyskaryosis or worse smear results, 134
(64% (95% CI: 57–71%)), were from the negative history group.
Table 2 shows an analysis according to whether women had two,
three or four negative smear episodes between ages of 40 and 49
years. For moderate dyskaryosis or worse, the risk compared with
the ‘positive’ group for two negative episodes was 0.60 (95% CI:
0.41–0.84), for three negative episodes 0.47 (95% CI: 0.32–0.71)
and for four negative episodes 0.25 (95% CI: 0.10–0.56). It is
Table 1 Result of the first primary smear test after age of 50 years by outcome of screening at ages of 40–49 years
Screening history between ages 40 and 49 years





smear after age of 50 years Number % Number % Number %
Negative 38633 91.71 6218 88.12 7569 89.35
Inadequate 2283 5.42 607 8.60 503 5.94
Borderline 895 2.12 172 2.44 287 3.39
Mild dyskaryosis 179 0.42 36 0.51 60 0.71
Moderate dyskaryosis 69 0.16 11 0.16 22 0.26
Severe dyskaryosis 43 0.10 6 0.09 20 0.24
Severe dyskaryosis-query invasive 3 0.01 0 0.00 1 0.01
Glandular neoplasia 19 0.05 6 0.09 9 0.11
Total 42124 7056 8471
Median no. of primary smears between ages of 40 and 49 years 3 3 3
Moderate dyskaryosis or worse (% of adequate smears and 95% CI) 134 (0.34% 95% CI: 0.28–0.40) 23 (0.36% 95% CI: 0.22–0.53) 52 (0.65% 95% CI: 0.48–0.85)
aNegative: at least two episodes, all of which were single smear episodes with a negative result and an action of return to routine recall.
bInadequate: one or more episodes that
included an inadequate smear result, but no abnormal cytology results.
cPositive: one or more episodes that included a smear with results of borderline cytology or worse.
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yrelatively uncommon for a woman to have had four routine
episodes between 40 and 49 (usually occurring when a women has
been screened every 3 years and her first smear included in the
study was at exactly the age of 40 years) and this group is therefore
small and the confidence limits wide.
The risks of cytological abnormality at the first primary smear
over age of 50 years in relation to number of negative smears at
ages of 40–49 years, relative to the ‘positive’ group and adjusting
for the effects of time since last smear, are shown in Table 3.
The relative risks of moderate dyskaryosis or worse for two, three
and four negative episodes were 0.58 (95% CI: 0.39–0.84), 0.49
(95% CI: 0.33–0.73) and 0.27 (95% CI: 0.12–0.61), respectively.
The results are similar to the unadjusted values and confirm that
after allowing for time since last smear there is a continuing
reduction in risk associated with increasing numbers of negative
smear episodes and suggestive evidence that the reduction may
be greatest for higher levels of disease (i.e., those most likely to
progress to invasive cancer).
Cancer registry information obtained by the CSEU has included
information on cases of CIN 3 in the study subjects, but the data
were not sufficiently complete or timely to be analysed statistically
as an outcome measure in this study. However, even in these
incomplete data there were 19 CIN 3 registrations and six invasive
cancer registrations from women in the ‘negative’ group (including
two invasive cancer registrations occurring in women with four
negative smear episodes between ages of 40 and 49 years), showing
clearly that a negative smear history between ages of 40 and 49
years does not preclude the occurrence of invasive cancer after age
of 50 years. We have checked the screening histories of the six
women with invasive cancers detected from the first smear after the
age of 50 years after negative smear histories. The smear test results
and the actions taken as a consequence of the smears are consistent
with the detection of such an abnormality, and hence we are
confident that the recorded abnormalities are not data entry errors.
The percentage of women referred to colposcopy (Table 4) for
the ‘negative’ group was 1.18% compared with 2.35% for the
‘positive group’, a relative risk of 0.48 (95% CI: 0.41–0.57).
The negative smear history group can be divided into women in 3-
or 5-yearly screening policy areas with two or three negative episodes
between ages 40 and 49 years. The percentage adequate smears with
mild or worse cytology was 0.67% (95% CI: 0.48–0.91) for two
negative episodes and 0.61% (95% CI: 0.48–0.76) for three negative
episodes. For women in 5 yearly screening areas these figures were
1.09% (95% CI: 0.91–1.30) and 0.80% (95% CI: 0.58–1.08),
respectively. As might be expected, the probability of mild or worse
cytology is higher in 5-yearly than 3-yearly screening policy areas.
DISCUSSION
Our results show that women over the age of 50 years with a
history of a minimum of two negative screening episodes between
the ages of 40 and 49 years, have a lower risk of cytological disease
found at screening than women with a ‘positive’ history. The
relative risk for borderline or worse disease at ages over 50 years
varied from 0.67 for women with two negative episodes to 0.52 for
women with four negative episodes compared with women with a
positive disease history. For severe dyskaryosis or worse the
relative risk decreased from 0.49 for two negative episodes to 0.13
for four negative episodes. There is therefore evidence that the risk
of higher levels of cytological disease is reduced more with
Table 2 Prevalence ratio (relative risk) of various levels of abnormal primary smear at the first smear over age of 50 years in relation to smear histories
between ages of 40 and 49 years
Screening history






No. PR (95% CI)
Mild or worse
No. PR (95% CI)
Moderate or worse
No. PR (95% CI)
Severe or worse
No. PR (95% CI)
Negative 39841 1208 0.61 (0.54–0.68)*** 313 0.56 (0.45–0.79)*** 134 0.52 (0.37–0.72)*** 65 0.43 (0.28–0.69***
Two negative episodes 17250 621 0.72 (0.63–0.82)*** 163 0.67 (0.53–0.86)*** 67 0.60 (0.41–0.84)** 34 0.52 (0.31–0.89)*
Three negative
episodes
17746 455 0.51 (0.45–0.59)*** 118 0.47 (0.36–0.62)*** 55 0.47 (0.32–0.71)*** 26 0.39 (0.22–0.68)***
Four negative episodes
a 4211 103 0.49 (0.39–0.61)*** 22 0.37 (0.22–0.59)*** 7 0.25 (0.10–0.56)*** 2 0.13 (0.01–0.50)***
Inadequate 6449 231 0.72 (0.61–0.84)*** 59 0.65 (0.47–0.90)** 23 0.55 (0.32–0.91)* 12 0.49 (0.23–0.99)*
Positive 7968 399 1.00 112 1.00 52 1.00 30 1.00
PR¼Prevalence ratio, 95% CI¼95% confidence interval. *Po0.05, **Po0.01, ***Po0.001.
aIn addition there were 634 women with 5+ negative smear episodes not included
in sub-group analysis because of small numbers and because the women are less likely to be representative of normal screening histories as a history of five or more episodes
over a 10-year period is not consistent with routine 3 (or 5) yearly screening.
Table 3 Odds ratios (relative risks) for various levels of abnormality for the first smear after the age of 50 years by number of negative smear episodes
between the ages of 40 and 49 years, after allowance for time since last smear
Exposure group
Borderline or
worse OR (95% CI)
Mild dyskaryosis or
worse OR (95% CI)
Moderate dyskaryosis
or worse OR (95% CI)
Severe dyskaryosis or
worse OR (95% CI)
Positive 1.00 1.00 1.00 1.00
Two negative episodes 0.67 (0.59–0.77)*** 0.62 (0.48–0.80)*** 0.58 (0.39–0.84)** 0.49 (0.30–0.83)**
Three negative episodes 0.54 (0.47–0.62)*** 0.50 (0.38–0.65)*** 0.49 (0.33–0.73)*** 0.39 (0.23–0.68)***
Four negative episodes 0.52 (0.42–0.66)*** 0.40 (0.25–0.64)*** 0.27 (0.12–0.61)*** 0.13 (0.03–0.56)**
**Po0.01, ***Po0.001.
Table 4 Probability of being referred for colposcopy, and prevalence
ratio (relative risk) of referral for colposcopy, during the first episode after
age of 50 years, by screening history
Screening history
between ages of









Negative 42124 477 (1.18) 0.48 (0.41–0.57)***
Inadequate 7056 121 (1.71) 0.73 (0.58–0.92)**
Positive 8471 199 (2.35) 1.00
**Po0.01, ***Po0.001.
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yincreasing numbers of earlier negative smear episodes than is the
case for lower levels of cytological disease. Of the 209 moderate
dyskaryosis or worse smear results 134 (64% (95% CI: 57–71%))
were from the negative history group and about 75–80% of these
women would be expected to have histological outcomes of CIN 2
or worse, based on the reported positive predictive value of
moderate dyskaryosis or worse for histology of CIN 2 or worse by
the local laboratories (Cervical Screening Programme bulletin,
2000–01). The negative history group were therefore clearly not a
group for whom withdrawal of screening would not be material in
public health policy terms.
Some of the women in the cohort will have received 5-yearly
screening invitations and some 3-yearly invitations, although in
practice because of the use of ‘opportunistic’ smear tests many
women in 5-year policy areas will have had screening at a shorter
interval than this (Flannelly et al, 2004). Women receiving 5 yearly
invitations were more likely to have had only two invitations. The
3-year policy areas may be considered more important to current
UK screening policy as they reflect the current screening policy
more closely. The results suggest a marginally reduced risk of mild
dyskaryosis or worse with number of negative episodes if 3-year
policy areas only are considered, but the conclusion remains that if
screening were discontinued in women with negative smear
histories an appreciable number of abnormalities would be missed.
The four Health Authority areas included in the study were
chosen because they had demographically similar populations to
each other and therefore might have similar disease risk, but had
different screening policies. Note that the screening history of
women in our cohort (if any) before 1985 is unknown and this is
why our study is limited to using only the screening history of
women between ages of 40 and 49 years to determine ‘exposure’
groups. The computerised national call-recall system started in
1988 and there is some possibility that records of a very few smears
from 1985 to 1987 may be missing from the files we used for these
years, but too few to have affected the results materially.
In general the risk of pre-invasive disease in women aged over 50
years is much lower than in younger women and therefore women
over the age of 50 years with a negative smear history (and
particularly with at least four negative smear episodes) are the lowest
identifiable risk group in our cohort. Nevertheless, our results,
suggest that if screening were discontinued for women over 50 years
with past negative smears, appreciable morbidity would be missed.
Selectively stopping screening at age 50 years for just those with four
serial negative smears would result in far less missed morbidity, but
with lower cost savings because the number of subjects with four
serial negatives was only one-eighth of the number with two or three
serial negatives. It is possible that taking account of negative smears
over a longer age-span than 40–49 years, or considering cessation of
screening at age of 55 years, would identify a group with clearer cost
benefit from cessation of screening, but the NHS screening
programme data do not, yet, run for a long enough period to assess
this. When longer follow-up becomes available, with the passage of
time, we will investigate risk of disease in women with a negative
history for the 15-year period between the ages of 35–49 years, and
outcomes for ages older than 55 years.
The cohort is formed from residents of Health Authority areas
in the South of England, which are likely to have a lower risk of
cervical cancer than the English average (Swerdlow and dos Santos
Silva, 1993). This is borne out by the percentage of adequate
smears having mild or worse dyskaryosis being 1.4% for women
aged of 50–54 years in England (Cervical screening programme,
England 2007–08 statistical bulletin), but only 0.9% in our cohort
sample. This suggests that the number of abnormalities being
missed would be even greater in the national screening programme
as a whole than in our cohort.
There have been a number of earlier investigations into the risk
of cervical disease in women aged over 50 years with negative
smear histories. Van Wijngaarden and Duncan (1993) reported
that of 26 women with micro-invasive and invasive cancer
registered in the Tayside area of Scotland at ages over 50 years,
none had had two or more serial negative 3-yearly smears. They
also reported that newly occurring cases of CIN were not seen in
women over 50 years who had been screened every 3 years. They,
therefore, suggested that women should cease screening at age 50
years if they had had three previous negative smears. Cruickshank
et al (1997) reported that among B9000 women regularly screened
every 3 years before the age of 50 years, one case of CIN 3 and one
case of invasive cancer were detected between 50 and 60, giving a
low disease rate, but with very wide confidence limits. Flannelly
et al (2004), by contrast, reported that 1.8% of 36512 women with
a negative smear history still showed subsequent dyskaryosis over
the age of 50. The period of screening considered was relatively
short, however; both the negative smears and the smear over age of
50 years had to have occurred within an 8-year period.
Other studies have investigated smear outcomes after negative
smears, but not specifically the question put forward by Van
Wijngaarden (Van Wijngaarden and Duncan, 1993), that is, risks
of abnormality detected at smears after the age of 50 years in
women with a negative history before that age. Armaroli et al
(2008) reported that the cumulative risk of CIN 2 or worse was at
least eightfold higher in women aged less than 50 years after one
earlier negative test than in women over 50 years with four serial
negative tests at any age. Armaroli et al (2008) also found, as we
did, that risks of abnormality decreased with increasing numbers
of negative smears – a finding also noted in a Canadian study
(Coldman et al, 2005).
Consideration of whether screening should cease beyond the age
of 50 years for those with a past negative history needs to take
account of both the potential benefits and harms of screening. The
potential harm associated with screening includes unnecessary
treatment from over-diagnosis and increased anxiety as well as the
cost of screening. It has been suggested that HPV testing could be
beneficial in identifying the small proportion of women still at risk
after the age of 50 years (Cruickshank et al, 2002). Sherlaw-
Johnson et al (1999) used mathematical modelling to study the
effects of withdrawing women at the age of 50 years from
screening, who had a recent history of negative results, or where
the last smear was negative and they tested negative for high-risk
HPV. They concluded that early withdrawal of women from the
programme could give resource savings of up to 25% for cytology
and 18% for colposcopy at the cost of an increased risk for cervical
cancer of up to two cases per 100000 women per year.
In conclusion, from our data the risk of pre-invasive cervical
disease at the age of 50 years in women with a history of multiple
negative smears between ages 40 and 49 years was moderately
reduced. At present, the NHS cervical screening programme using
the national call-recall system (which started in 1988) can only
determine a negative history over a limited period of time, and the
same was therefore true for our study. Our data give evidence that
the risk of abnormality, and particularly the risk of more severe
pre-invasive lesions, may decline with increasing numbers of earlier
negative smear episodes. Longer follow-up of the cohort will enable
the outcome of women with more extensive negative histories to be
studied, to determine if there are potentially very low risk groups for
whom further screening may not be the best use of resources.
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